100 VANGUARD BOULEVARD,
MALVERN , PA, 19355
MALVERN , PA, 19355
Summary
The fund seeks capital appreciation in the long term by investing in small-and mid-size companies in the United States.
The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
Next, the research team invests in companies that are estimated to trade below their fair values.
The More
Link
Directors
Nov 14, 2023- Tara Bunch
- Grant Reid
- F. Joseph Loughrey
- Mortimer J. Buckley
- Scott C. Malpass
- Andre F. Perold
- Sarah Bloom Raskin
- Deanna Mulligan
- Mark Loughridge
- David Thomas
- Peter F. Volanakis
- Emerson U. Fullwood
Chief Compliance Officer
- Jacqueline Angell
Fund Manager(s)
- William Teichner
- Eugene Fox
- Robert Kirkpatrick
- Rachel Matthews
- Robert Fields
- Rushan Jiang
- Kenneth Kuhrt
- John Rogers
Price
- 52-Week High/Low
- $49.91 - $37.92
- Turnover
- 30.8%
- Expense Ratio
- 0.49%
Company Name |
Holding |
| Halozyme Therapeutics Inc | 0.79 % |
| Envista Holdings Corp | 0.73 % |
| First BanCorp/Puerto Rico | 0.73 % |
| SITE Centers Corp | 0.72 % |
| Insight Enterprises Inc | 0.68 % |
| Tidewater Inc | 0.67 % |
| Carpenter Technology Corp | 0.65 % |
| Bread Financial Holdings Inc | 0.57 % |
| Silicon Motion Technology Corp | 0.55 % |
| LXP Industrial Trust | 0.51 % |
| More | 0.51 % |
Advisor
Documents
Performance
YTD
-
3 Year
1.06%
5 Year
36.55%
Best
38.14%
2013
Worst
-17.2%
2022
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | - | 6.6% | 2.2% | -3% | 16.7% | -37.7% | 12.8% | - | 1.4% | 2.3% |
| Q2 | - | -3.9% | 4% | -15.1% | 4.7% | 23.7% | 2.7% | 7.2% | 1.4% | 2.1% |
| Q3 | - | - | -3.6% | -6.7% | -5.3% | 1.1% | -0.5% | 3.1% | 5.5% | 6.2% |
| Q4 | - | - | 11.4% | 7.7% | 6.6% | 31.3% | 6.3% | -18.9% | 3.5% | 8.8% |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | -2% | 4.1% | 4.5% | -7% | - | - | - | - | - | - | - | - |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 2% | 12% | -17% | 23% | 2% | 25% | -13% | 13% | 21% |
Alpha
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| VEVFX | - | 2% | 12% | -17% | 23% | 2% | 25% | -13% | 13% | 21% |
| Russell Midcap | - | - | - | -3% | 26% | 3% | 24% | -14% | 11% | 17% |
| Alpha | - | 2% | 12% | -14% | -3% | -0% | 1% | 1% | 2% | 3% |